BRPI0511671A - tiazolacético substituìdo como ligantes de crth2 - Google Patents

tiazolacético substituìdo como ligantes de crth2

Info

Publication number
BRPI0511671A
BRPI0511671A BRPI0511671-6A BRPI0511671A BRPI0511671A BR PI0511671 A BRPI0511671 A BR PI0511671A BR PI0511671 A BRPI0511671 A BR PI0511671A BR PI0511671 A BRPI0511671 A BR PI0511671A
Authority
BR
Brazil
Prior art keywords
ring
thiazolacetic
crth2
carboxyl
report
Prior art date
Application number
BRPI0511671-6A
Other languages
English (en)
Inventor
Trond Ulven
Thomas Frimurer
Oystein Rist
Evi Kostenis
Thomas Hoegberg
Jean-Marie Receveur
Marie Grimstrup
Original Assignee
7Tm Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0412198A external-priority patent/GB0412198D0/en
Priority claimed from GB0414194A external-priority patent/GB0414194D0/en
Priority claimed from GB0424016A external-priority patent/GB0424016D0/en
Application filed by 7Tm Pharma As filed Critical 7Tm Pharma As
Publication of BRPI0511671A publication Critical patent/BRPI0511671A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

TIAZOLACéTICO SUBSTITUìDO COMO LIGANTES DE CRTH2. Compostos da fórmula (I) são úteis para o tratamento de doença responsiva à modulação da atividade do receptor CRTH2, tal como asma, rinite, síndrome da via aérea alérgica e rinobronquite alérgica: onde X~ 1~ é -S-, -O-, -N=N-, -NR~ 7~-, -CR~ 7~=CR~ 8~-, -CR~ 7~=N-, onde R~ 7~ and R~ 8~ são independentemente hidrogênio ou C~ 1~ -C~ 3~ alquila; A é um grupo carboxila - COOH ou um biolsóstero de carboxila; os anéis Ar¬ 2¬ e Ar¬ 3¬, cada um, independentemente, representam um anel fenila ou heteroarila monocíclico de 5 ou 6 membros, ou um sistema de anel bicíclico consistindo em um anel carbocíclico ou heterocíclico de 5 ou 6 membros que é benzofundido ou fundido a um anel heteroarila monocíclico de 5 ou 6 membros, o dito anel ou sistema de anel sendo opcionalmente substituído; o anel B é definido para Ar¬ 2¬ e Ar¬ 3¬, ou um anel N-pirrolidinila, N-piperidinila ou N-azepinila opcionalmente substituído; s é 0 ou 1; L1, L2 e L4 são radicais ligantes conforme definido no relatório; Q1 e Q2 representam substituintes conforme definido no relatório.
BRPI0511671-6A 2004-05-29 2005-05-30 tiazolacético substituìdo como ligantes de crth2 BRPI0511671A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0412198A GB0412198D0 (en) 2004-05-29 2004-05-29 Medicinal use of receptor ligands
GB0414194A GB0414194D0 (en) 2004-06-24 2004-06-24 Medicinal use of receptor ligands
GB0424016A GB0424016D0 (en) 2004-10-29 2004-10-29 Medicinal use of receptor ligands
PCT/EP2005/005882 WO2005116001A1 (en) 2004-05-29 2005-05-30 Substituted thiazoleacetic as crth2 ligands

Publications (1)

Publication Number Publication Date
BRPI0511671A true BRPI0511671A (pt) 2008-01-02

Family

ID=34968996

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511671-6A BRPI0511671A (pt) 2004-05-29 2005-05-30 tiazolacético substituìdo como ligantes de crth2

Country Status (13)

Country Link
US (1) US20080119456A1 (pt)
EP (1) EP1758874A1 (pt)
JP (1) JP2008503447A (pt)
KR (1) KR20070044404A (pt)
AU (1) AU2005247610A1 (pt)
BR (1) BRPI0511671A (pt)
CA (1) CA2568742A1 (pt)
CR (1) CR8837A (pt)
EA (1) EA200602288A1 (pt)
IL (1) IL179693A0 (pt)
MX (1) MXPA06013924A (pt)
NO (1) NO20066049L (pt)
WO (1) WO2005116001A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427381D0 (en) * 2004-12-14 2005-01-19 Novartis Ag Organic compounds
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
MX2010009162A (es) 2008-02-22 2010-12-21 Radius Health Inc Moduladores selectivos del receptor de androgeno.
JP5535931B2 (ja) * 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
CA2750565C (en) * 2009-01-30 2015-10-20 Glaxosmithkline Llc Crystalline n-{(1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
US8674115B2 (en) 2009-12-23 2014-03-18 Ironwood Pharmaceuticals, Inc. CRTH2 modulators
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
PT2568806T (pt) 2010-05-12 2016-08-05 Radius Health Inc Regimes terapêuticos
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
ES2550319T3 (es) 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
KR20140113667A (ko) 2011-12-16 2014-09-24 아토픽스 테라퓨릭스 리미티드 호산구성 식도염의 치료를 위한 ｃｒｔｈ2 길항제 및 양성자 펌프 저해제의 조합
RS63311B1 (sr) 2016-06-22 2022-07-29 Ellipses Pharma Ltd Ar+ metode lečenja raka dojke

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL133916A0 (en) * 1997-07-10 2001-04-30 Janssen Pharmaceutica Nv Il-5 inhibiting 6-azauracil derivatives
US6268363B1 (en) * 1997-11-28 2001-07-31 Lg Chemical Ltd. Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
EP0987265A1 (en) * 1998-09-18 2000-03-22 Janssen Pharmaceutica N.V. Interleukin-5 inhibiting 6-azauracil derivatives
TR200200310T2 (tr) * 1999-08-06 2002-08-21 Janssen Pharmaceutica N.V. Interlökin-5 inhibe eden 6-azaurasil türevleri.
WO2003006015A1 (en) * 2001-07-13 2003-01-23 Bristol-Myers Squibb Pharma Company Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
CA2568742A1 (en) 2005-12-08
EA200602288A1 (ru) 2007-10-26
JP2008503447A (ja) 2008-02-07
IL179693A0 (en) 2007-05-15
CR8837A (es) 2008-03-18
EP1758874A1 (en) 2007-03-07
AU2005247610A1 (en) 2005-12-08
MXPA06013924A (es) 2007-07-18
WO2005116001A1 (en) 2005-12-08
NO20066049L (no) 2007-02-27
US20080119456A1 (en) 2008-05-22
KR20070044404A (ko) 2007-04-27

Similar Documents

Publication Publication Date Title
BRPI0511676A (pt) uso medicinal de ligandos receptores
El-Enany et al. Synthesis and molecular docking of some new bis-thiadiazoles as anti-hypertensive α-blocking agents
CR10381A (es) Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas
Mete et al. Synthesis and carbonic anhydrase inhibitory activities of new thienyl-substituted pyrazoline benzenesulfonamides
Rosenthal et al. Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk)
BR0312129A (pt) Derivados de espiroindolinapiperidina
Hou et al. Asymmetric synthesis of polysubstituted 4-amino-and 3, 4-diaminochromanes with a chiral multifunctional organocatalyst
BRPI0911243B8 (pt) derivados de benzofurano, benzotiofeno, benzotiazol, e composição farmacêutica
BRPI0620408B8 (pt) derivados de pirimidinil aril uréia sendo inibidores de fgf, seus usos, e preparação farmacêutica
BRPI0510736A (pt) compostos de amido e seu uso como produtos farmacêuticos
Ramanathan et al. Preparation of quinazolines via a 2+ 2+ 2 annulation from aryldiazonium salts and nitriles
NO20075623L (no) Benzodioksan- og benzodioksolanderivater og deres anvendelse
CO6140033A2 (es) Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia
Havrylyuk et al. Synthesis and anticancer activity of novel nonfused bicyclic thiazolidinone derivatives
Lu et al. One-pot synthesis of unsymmetrical bis-heterocycles: Benzimidazole-, benzoxazole-, and benzothiazole-linked thiazolidines
CY1118568T1 (el) Παραγωγα ιμιδαζοπυριδαζινης ως διαμορφωτες του υποδοχεα gabaa
BR112012032813A2 (pt) composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença ou condição.
BRPI0820779B8 (pt) compostos derivados de 4-amino-pirimidina, composição farmacêutica, uso e processo para preparação dos referidos compostos
Edraki et al. N‐(2‐(Piperazin‐1‐yl) phenyl) arylamide Derivatives as β‐Secretase (BACE1) Inhibitors: Simple Synthesis by Ugi Four‐Component Reaction and Biological Evaluation
CY1112679T1 (el) Κινολινες και θεραπευτικη χρηση αυτων
BRPI0811200A8 (pt) Tetra-hidrobenzapinas arilóxi- e heteroarilóxi-substituídas e uso das mesmas para bloquear percepção de norepinefrina, dopamina, e serotonina
NO20066049L (no) Substituerte tiazoleddiksyrer som CRTH2-ligandere
BRPI0513891B8 (pt) derivados de propenil piperazina substituídos, seu uso como novos inibidores de histona deacetilase, composição farmacêutica, combinação e processo de preparação destes
Zinad et al. An efficient synthesis of novel imidazo-aminopyridinyl derivatives from 2-chloro-4-cyanopyridine
ATE480239T1 (de) Angiogeneseinhibitoren

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2139 DE 03/01/2012.